Astion Pharma

Action Pharma A/S is a research and development-focused biotechnology company. It discovers and develops new drugs and therapeutic concepts for the treatment of cardiovascular diseases, inflammatory diseases, as well as metabolic disorders such as type II diabetes and obesity. The company’s pipeline includes AP214, a modified α-MSH peptide analog used to treat postoperative renal injury associated with cardiac surgery.